Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies

Multiple myeloma - lenalidomide: review decision - November 2012 information

Appendix A: GE Decision paper (PDF 74 KB)

Multiple myeloma - lenalidomide: review proposal - March 2012 information

Appendix A: provisional matrix of stakeholders (PDF 122 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 148 KB)

TA171 Multiple myeloma - lenalidomide: review update - November 2011 information

TA171 Multiple myeloma - lenalidomide: review update - January 2011 information

Multiple myeloma - lenalidomide: final appraisal determination information

Multiple myeloma - lenalidomide: final appraisal determination (PDF 132 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation

Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) issued October 2008 (PDF 154 KB)

Response to consultee, commentator and public comments on the second Appraisal Consultation Document (ACD) issued January 2009 (PDF 145 KB)

Letter from the Department of health RE: Patient Access Scheme for lenalidomide for the treatment of multiple myeloma (PDF 24 KB)

Letter from Celgene sent on 26th February 2009 (PDF 30 KB)

Consultee and commentator comments on the ACD

Celgene (PDF 31 KB)

Department of Health (PDF 9.5 KB)

Janssen-Cilag (PDF 59 KB)

Macmillan Cancer Relief (PDF 24 KB)

Myeloma UK (PDF 33 KB)

Royal College of Nursing (PDF 18 KB)

Royal College of Pathologists (PDF 135 KB)

Royal College of Physicians on behalf of NCRI/RCP/RCR/ACP/JCCO (PDF 35 KB)

Sandwell PCT (PDF 22 KB)

UK Myeloma Forum and British Society for Haematology (PDF 14 KB)

Public comments on the ACD (PDF 42 KB)

Multiple myeloma - lenalidomide: appraisal consultation document 2

Multiple myeloma - lenalidomide: appraisal consultation document 2 information

Multiple myeloma - lenalidomide: comments on the ACD issued in October 2008

Extra analysis

Addendum to the ERG report (PDF 110 KB)

Addendum to the pre-meeting briefing: end of life - a quantitative exploration (PDF 24 KB)

Non-manufacturer comments on the ACD issued in October 2008

Department of Health (PDF 6.8 KB)

Janssen-Cilag (PDF 51 KB)

Macmillan Cancer Support (PDF 39 KB)

Myeloma UK, Leukaemia CARE, Leukaemia Research and the Rarer Cancers Forum (PDF 66 KB)

Royal College of Nursing (PDF 18 KB)

Royal College of Physicians, Medical Oncology Joint Special Committee (PDF 22 KB)

Royal College of Pathologist (PDF 71 KB)

Sandwell PCT (PDF 15 KB)

UK Myeloma Forum and British Society for Haematology (PDF 17 KB)

Welsh Assembly Government (PDF 12 KB)

Manufacturer comments on the ACD issued in October 2008

Celgene response to ACD (PDF 101 KB)

Celgene response to ERG lenalidomide report (PDF 160 KB)

Letter to DH regarding proposed patient access scheme (PDF 139 KB)

Response to questions from NICE on ACD comments (PDF 34 KB)

NICE letter to Celgene requesting clarification on their ACD response (PDF 28 KB)

Public comments on the ACD issued in October 2008

Letters (PDF 1012 KB)

Emails (PDF 92 KB)

Web comments (PDF 774 KB)

Letter to NICE from the Department of Health RE: Patient Access Scheme for lenalidomide for the treatment of multiple myeloma (PDF 24 KB)

Multiple myeloma - lenalidomide: appraisal consultation 

Multiple myeloma - lenalidomide: appraisal consultation document information

Multiple myeloma - lenalidomide: evaluation report

Multiple myeloma - lenalidomide: pre-meeting briefing (PDF 133 KB)

Multiple myeloma - lenalidomide: evidence review group report (PDF 997 KB)

Non-manufacturer submissions

Myeloma UK (PDF 54 KB)

Royal College of Nursing (PDF 14 KB)

Royal College of Physicians (on behalf of the NCRI, RCP, RCR, ACP and JCCO) (PDF 36 KB)

Royal College of Pathologists (PDF 124 KB)

UK Myeloma Forum and British Society For Haematology (PDF 125 KB)

Manufacturer submission

Celgene (PDF 1.44 MB)

NICE request for clarification (PDF 288 KB)

Response from Celgene to request for clarification: Additional information: Part 1 (PDF 26 KB)

Response from Celgene to request for clarification: Additional information: Part 2 (PDF 17 KB)

Multiple myeloma - lenalidomide: Response from Celgene to request for clarification (PDF 288 KB)

Expert written personal statements

Brown (PDF 59 KB)

Cavenagh (PDF 45 KB)

Low (PDF 18 KB)

Schey (PDF 42 KB)

Multiple myeloma - lenalidomide: final scope (PDF 32 KB)

Multiple myeloma - lenalidomide: draft scope (pre-referral) (PDF 34 KB)

Multiple myeloma - lenalidomide: response to comments on the draft scope (pre-referral) (PDF 147 KB)

Multiple myeloma - lenalidomide: provisional matrix of consultees and commentators (PDF 30 KB)

Multiple myeloma - lenalidomide: response to comments on provisional matrix of consultees and commentators (PDF 51 KB)